...
首页> 外文期刊>Journal of endovascular therapy: an official journal of the International Society of Endovascular Specialists >Advances in endovascular techniques to treat failing and failed hemodialysis access.
【24h】

Advances in endovascular techniques to treat failing and failed hemodialysis access.

机译:治疗失败和失败的血液透析通路的血管内技术的进步。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

During the decade since JEVT was inaugurated, we have witnessed the growing application of endovascular techniques for arteriovenous (AV) access in parallel with the evolution of endovascular therapy for arterial pathology. To date, few if any technologies have compared with balloon angioplasty for treating venous anastomotic stenosis, the most common cause of access failure. Only one device, which incorporates the principles of access graft design and self-expanding stent technology, has been uniquely conceived for this pathology. The encapsulated polytetrafluoroethylene stent-graft has achieved reasonable preliminary results, but randomized data is forthcoming. Technology to clear the clot from a thrombosed graft continues to evolve, but will never be as cost-effective as simple balloon thrombectomy. However, the pressure placed on providers to perform all percutaneous interventions and move away from open techniques continues to fuel interest in this component of treatment. Finally, the pursuit of acompletely percutaneous AV access continues. As with endovascular procedures in general, whether or not the procedure is cost-effective or time-consuming seems to take a back seat to the all-percutaneous approach that so many seem to converge upon. Moreover, as most autogenous fistulas and AV grafts can be created with minimal incisions under local anesthesia, the pursuit of a completely percutaneous access system seems more like an academic exercise than a practical application of technology. We must try and avoid the tendency to minimize invasiveness expensive), such as limiting ourselves to only percutaneous methods. Given the increasing pressure to have an all autogenous access program, current techniques that apply well in prosthetic grafts will need to be modified to accommodate the different biology of a native fistula. Clearly, the enlarging end-stage renal disease population will continue to provide endovascular specialists with clinically challenging problems requiring new and revolutionary technology.
机译:自JEVT启用以来的十年中,我们目睹了血管内技术在动静脉(AV)通路方面的日益增长的应用以及与血管内疾病病理学疗法的发展同步。迄今为止,很少有技术能够与球囊血管成形术相比来治疗静脉吻合口狭窄,这是通行失败的最常见原因。对于这种病理学,只有一种设备能够完美地融合了通路移植物设计和自扩张支架技术的原理。封装的聚四氟乙烯支架移植物已取得合理的初步结果,但即将获得随机数据。从血栓形成的移植物中清除血块的技术仍在不断发展,但永远不会比简单的球囊血栓切除术具有更高的成本效益。然而,施加于提供者以执行所有经皮干预并远离开放技术的压力继续激发对该治疗组成部分的兴趣。最后,继续追求完全经皮的AV通路。与一般的血管内手术一样,该手术是经济有效还是耗时的,似乎使许多人似乎都趋于一致的全皮手术方法退居二线。此外,由于可以在局部麻醉下以最小的切口创建大多数自体瘘和AV移植物,因此,追求完全经皮进入系统似乎更像是一项学术练习,而不是技术的实际应用。我们必须设法避免将侵入性降到最低的趋势(例如将自身局限于仅经皮方法)。鉴于采用全自体进入程序的压力越来越大,需要对适用于假体移植的现有技术进行修改,以适应天然瘘管的不同生物学特性。显然,不断增加的终末期肾脏疾病人群将继续为血管内专家提供需要新技术和革命性技术的临床难题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号